Arcutis Biotherapeutics (ARQT) Raw Materials (2022 - 2026)

Arcutis Biotherapeutics' Raw Materials history runs 5 years deep, the most recent figure standing at $16.4 million for Q1 2026.

• In Q1 2026, Raw Materials rose 116.71% year-over-year to $16.4 million; the TTM figure through Mar 2026 stood at $16.4 million (up 116.71% YoY), while the FY2025 annual figure was $5.0 million, up 17.37% from the prior year.
• Raw Materials for Q1 2026 stood at $16.4 million, up from $5.0 million in the prior quarter.
• The five-year high for Raw Materials was $16.4 million in Q1 2026, with the low at $3.5 million in Q3 2022.
• The 5-year median for Raw Materials is $6.5 million (2023), against an average of $7.3 million.
• The sharpest annual moves came in 2023 and 2024: Raw Materials soared 220.64% in 2023, then slumped 63.49% in 2024.
• Arcutis Biotherapeutics' Raw Materials stood at $5.7 million in 2022, then jumped by 75.84% to $10.0 million in 2023, then sank by 56.79% to $4.3 million in 2024, then rose by 17.37% to $5.0 million in 2025, then soared by 224.57% to $16.4 million in 2026.
• Business Quant data shows ARQT's Raw Materials at $16.4 million in Q1 2026, $5.0 million in Q4 2025, and $6.1 million in Q3 2025.